|
| Management and cause analysis of platelet transfusion refractoriness |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.46701/APJBG.2018042018134 |
| KeyWord:platelet transfusion refractoriness alloimmunization management |
| Author | Institution |
| Xiangyan Huang |
Department of Blood Transfusion, The 960th Hospital of PLA, Jinan 250031, shandong China. |
|
| Hits: 2211 |
| Download times: 2147 |
| Abstract: |
| Platelet transfusion refractoriness (PTR) can be defined as the less increment of platelet count than expected after platelets transfusion, which is a challenging and expensive problem often observed in platelet-transfusion-dependent patients. Although PTR occurs most frequently due to non-immune causes, a significant minority is still caused by immune factors. The most important factor in immune dependent PTR is alloimmunization against Class I human leukocyte antigens (HLAs) or human platelet antigens (HPAs). The compatible platelets can be provided to immune-mediated patients using platelet crossmatching, HLA matching, and antibody specificity testing. These measures-aimed to eliminate donor-specific HLA antibodies will lead to the improved clinical management of PTR patients, caused by severe alloimmunization. |
| Close |
